Children with Dravet syndrome, a severe form of epilepsy that begins in infancy, experience seizures, usually for their entire life. They are at high risk of sudden unexpected death in epilepsy (SUDEP) and can also develop intellectual disability and autism. Available treatments typically fail to improve these symptoms.
Now, a group of scientists at reports new findings in the journal Science Translational Medicine that could guide the development of better therapeutic strategies for Dravet syndrome and related conditions.
The researchers previously discovered, in a mouse model of Dravet syndrome, that genetically removing the protein tau from the entire body during embryonic development reduces epilepsy, SUDEP, and autism-like behaviors. In the new study, they pinpoint the key cell type in the brain in which tau levels must be reduced to avoid these problems. They also show that lowering tau is still effective in mice when the intervention is delayed until after their birth.
“Our findings provide new insights into the cellular mechanisms by which tau reduction prevents abnormal overexcitation in the brain,” says the senior author. “They are also encouraging from a therapeutic perspective, since in humans, initiating treatment after birth is still more feasible than treating embryos in the womb.”
Tau is a promising therapeutic target not only for Dravet syndrome, but also for a variety of other conditions, including different types of epilepsy and some forms of autism, as well as Alzheimer’s disease and related neurodegenerative disorders.
A well-functioning brain depends on the correct balance between the activity of excitatory and inhibitory neurons—the former stimulate the activity of other neurons, while the latter suppress it. Dravet syndrome causes an imbalance between these types of cells, resulting in abnormally high and synchronized activity in brain networks that can manifest as seizures and other symptoms.
The researchers recently showed that removing tau from the entire brain changes the activities of both excitatory and inhibitory neurons, although in different ways. The current study aimed to determine whether it is more important to reduce tau in excitatory or inhibitory neurons.
For this purpose, the scientists used genetic tools to eliminate tau selectively from one or the other cell type in the Dravet mouse model. They found that removing tau from excitatory neurons reduced disease manifestations, whereas removing tau from inhibitory neurons did not.
“This means that tau production in excitatory neurons sets the stage for all these abnormalities to occur, including autistic behaviors, epilepsy, and sudden unexpected death,” says the senior author.
While the genetic approaches the scientists used to remove tau from specific cell types are effective and precise, they are not yet easy to use as a therapeutic intervention in humans. So, the team turned to a more practical option: global tau reduction in the brain with DNA fragments known as antisense oligonucleotides, or ASOs. The scientists delivered an anti-tau ASO into the brain of mice 10 days after birth and found that most symptoms of Dravet syndrome were gone 4 months later.
“We observed a robust reduction of SUDEP, seizure activity, and repetitive behaviors,” says the first author of the study.
In addition, the ASO treatment had no obvious side effects.
“We are excited about these findings, especially since another anti-tau ASO has already undergone a Phase I clinical trial in people with Alzheimer’s disease,” says the author. “It could be useful to consider this strategy also for Dravet syndrome and related conditions. However, defining the optimal timing for treatment initiation will be key, as the window of opportunity might be quite narrow.”
Although Alzheimer’s disease, epilepsy, and autism have diverse causes, they all seem to be associated with abnormally high ratios between excitatory and inhibitory neuronal activities—and this abnormality could potentially be fixed by tau-lowering therapeutics.
Still, a treatment based on anti-tau ASOs would involve repeated spinal taps, a procedure most people would rather avoid. Therefore, the senior author is partnering with Takeda Pharmaceuticals to develop small molecules that could reduce brain tau levels when administered as a pill.
https://www.science.org/doi/10.1126/scitranslmed.abm5527
Reducing tau levels in excitatory neurons soon after birth can prevent Dravet syndrome in mice
- 856 views
- Added
Latest News
Liver biopsy to predict pan…
By newseditor
Posted 03 Jul
Significant differences in…
By newseditor
Posted 02 Jul
Serotonin 2C receptor regul…
By newseditor
Posted 02 Jul
First TB specific PET scan
By newseditor
Posted 02 Jul
Molecular mechanisms of som…
By newseditor
Posted 01 Jul
Other Top Stories
How Chromosomes 'Cheat' for the Chance to Get Into an Egg
Read more
Genetic variation in glia-neuron signalling modulates ageing rate
Read more
Skin pigmentation far more complex than previously known
Read more
Modified CRISPR to epigenetically treat diabetes, kidney disease, m…
Read more
Gene for bad breath found!
Read more
Protocols
Monitoring norepinephrine r…
By newseditor
Posted 01 Jul
BicemuS: A new tool for neu…
By newseditor
Posted 26 Jun
Deciphering spatial domains…
By newseditor
Posted 23 Jun
High-throughput volumetric…
By newseditor
Posted 21 Jun
Bioengineered human colon o…
By newseditor
Posted 14 Jun
Publications
Propionic acid promotes neu…
By newseditor
Posted 03 Jul
Association of genetic risk…
By newseditor
Posted 03 Jul
Emerging treatments in HER2…
By newseditor
Posted 02 Jul
Neuroimaging epicenters as…
By newseditor
Posted 02 Jul
Divergent landscapes of A-t…
By newseditor
Posted 02 Jul
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar